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Learning objectives
-What is Marine-Lenhart Syndrome ?.
-Pathology -Diagnosis: laboratory and imaging findings.
-Treatment.
Background Introduction
The association of Graves disease (also known as "diffuse toxic goiter" such as Basedow disease or Morbus Basedow in German speaking countries) with autonomously functioning thyroid nodules constitutes the Marine-Lenhart Syndrom (MLS).
Robert Graves first identified the association of goiter, palpitations, and exophthalmos in three cases in 1834, although Caleb Parry had published details of a case in 1825. Carl von Basedow described exophtalmic goiter in a relatively large number of cases in 1844. It was Henry Plummer in 1911 who clearly distinguised exophtalmic goiter from adenomatous goiter. But at the same year, 1911, David Marine and Carl Lenhart described hyperhyroidism due to Graves disease and concomitant functioning follicular thyroid adenomas in 8 cases. Consequently, this syndrom has been named in their honour.
Incidence
Graves disease has an annual incidence of about 5 per 10.000 people and it is the most common cause of hyperthyroidism (70-80%) followed by autonomously functioning thyroid nodules. In USA the incidence of extrapolations for Graves´ diseases is about 136.000 cases per year, the prevalence of MLS appears to lie between 2,7 and 4,1%. In selected patients with hyperthyroidism remitted to our hospital for radiodine therapy in the last 8 years the incidence of MLS was 3%.
Pathology
Graves´ disease is an autoimmune disorder, meaning the immune system makes antibodies called thyroid-stimulating immunoglobulin (TSI), which bind to and activate the thyrotropin receptor on thyroid cells attaching them. TSI mimics the action of TSH and stimulates the gland to increase thyroid hormones T3 and T4.
Solitary toxic nodule or toxic multinodular (Plummer´s disease) are usually hyperfunctioning follicular adenomas releasing thyroid hormones.
Therefore, Graves´ disease and toxic nodular goiter both causes thyreotoxicosis by different pathophysiological mechanisms, but in the MLS there is a coexistence of both pathologies.
The pathogenesis of MLS is not clear and may be as follows:
1.
Initially hyperthyreodism caused by Graves disease followed later with toxic nodules 2.
Initially development of autonomously functioning thyroid nodules followed later by Graves disease 3.
Both pathologies are instaured simultaneously Genetics alterations of the TSH receptors and the presence of TSH antireceptors autoantibodies in the development of MLS have been postulated.
In some case reports a hyperthyroidism induced only by a toxic nodule with additional orbitopathy considered as only manifestation of euthyroid Graves disease has been hypothesized.
Besides, radiodine therapie with I 131 could be an activating factor
Clinical presentation
The most common signs/symptoms of MLS are the same for every cause of hyperthyroidism: nervosity, palpitations, loss of weight despite increased apetite, increased sweating, with possible cardiac complications, such as heart failure, tachycardia or atrial fibrillation. It must be taken into consideration that in the elderly the clinical manifestation of hyperthyroidism is often atypical and can easily be attributed to other medical conditions. In elder patients signs and symptoms of thyreotoxicosis are frequently related to cardiovascular, gastrointestinal and neuropsychiatric disorders. Most often there is an occurrence of atrial fibrillation, worsening of cardiac failure and angina pectoris, weight loss, anorexia, constipation and cognitive impairment.
A thyroid associated ophthalmopathy is also possible in MLS, but rare.
In our 28 cases of MLS only 2 patients (7%) presented a Graves opththalmopathy.
Imaging findings OR Procedure details Laboratory tests/examinations
• TSH (Thyroid Stimulating Hormone): suppresed (usually <0.01 mU/l). • Thyroid hormones FT3 and FT4: increased or in the upper limit (manifest or subclinical hyperthyroidism) (amount depending of test-levels).
• TSH receptor antibodies (TRAb): increased in >80%.
Imaging findings Scintigraphy
• In Graves disease Tc-99m pertechnetate or iodine-123 (for diagnostic) or iodine-131 (for quantification of uptake for planning radiodine therapy) thyroiid scan shows homogenously increased activity throughout the gland with high target-to-background levels ( Fig. 1 ).
• In toxic adenoma the scan shows a single hot nodule with no activity in the rest of the gland (Fig. 2 ).
• In MLS the scan shows a diffuse increased uptake of the thyroid but also one (or more areas) of focal activity (hot nodules) (Figs, 3-8).
Technetium uptake (TcTU) is increased (2-10%). The radioactive iodine uptake (RAIU) is usually greater than 40% in patients with MLS.
A diffuse increased isotope captation with one (or more) hot nodule(s) and with iodine-131-uptake greater than 50% allows the scintigraphic diagnosis of MLS.
Ultrasound
In MLS grayscale US shows a normal or slight enlarged gland with one or more nodules. These nodules are usually hypoechoic or isoechoic (in about 76%), and only hyperechoic in about 24%. When an euthyroid state or, at least, a subclinical hyperthyroidism is reached, a definitive management of MLS must be performed: Surgery or radiodine therapy
Radioiodine is considered the definitive treatment of choice in patients with MLS. In our collective, 25/28 patients underwent one I-131-Therapy, with succes in 92%. Only 2/25 Patients needed a second radiodine therapy. After that the hyperthyroidism was also eliminated. That means that with 1-2 radiodine therapies a succesful definitive management of MLS can be obtained. 
